Current Paradigms for the Use of HER2-Targeted Therapy in Early-Stage Breast Cancer-Reference-Cited by-同舟云学术

Current Paradigms for the Use of HER2-Targeted Therapy in Early-Stage Breast Cancer

Published:2008-12 Issue: Volume:8 Page:S157-S165
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Bedard Philippe L.,Piccart-Gebhart Martine J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference55 articles.

1. Sledge GW. Targeting HER2 in the adjuvant setting. Presented at: the 2005 American Society of Clinical Oncology Annual Meeting; May 13-17, 2005; Orlando, FL.

2. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials;Dahabreh;Oncologist,2008

3. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Eng J Med,2005

4. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer;Perez;J Clin Oncol,2007

5. Real-world performance of HER2 testing–National Surgical Adjuvant Breast and Bowel Project experience;Paik;J Natl Cancer Inst,2002

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antioxidant and Anti-Breast Cancer Properties of Hyaluronidase from Marine Staphylococcus aureus (CASMTK1);Journal of Marine Science and Engineering;2023-04-03

2. Therapeutic Protein-Based Vaccines;Protein-based Therapeutics;2023

3. Efficacy and Safety of Therapeutic Proteins;Protein-based Therapeutics;2023

4. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics;PLOS ONE;2022-02-25

5. Epigenetic modulators combination with chemotherapy in breast cancer cells;Cell Biochemistry and Function;2021-02-20